Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12719262 | 0.89 | FFAR1 (0.43) | FAAHMEN1KMT2A | |
| SCHEMBL12718518 | 0.88 | S1PR1 (0.35) | FAAHGABRA1GABRB2S1PR1S1PR3 | |
| SCHEMBL10303052 | 0.88 | FFAR4 (0.37) | FAAHFFAR4MEN1KMT2ANPSR1 | |
| SCHEMBL12718841 | 0.87 | S1PR1 (0.34) | FAAHGABRA1GABRB2S1PR1S1PR3 | |
| SCHEMBL12717002 | 0.87 | FFAR4 (0.35) | FAAHFFAR4MEN1KMT2ANPSR1 | |
| SCHEMBL13586170 | 0.87 | FFAR4 (0.35) | FAAHFFAR4MEN1KMT2ANPSR1 | |
| SCHEMBL12823851 | 0.86 | FFAR1 (0.43) | FAAHMEN1KMT2A | |
| SCHEMBL10303036 | 0.86 | FFAR4 (0.35) | FAAHFFAR4MEN1KMT2ANPSR1 | |
| SCHEMBL13586388 | 0.86 | FAAH (0.42) | FAAHFFAR4S1PR1 | |
| SCHEMBL10303179 | 0.86 | FFAR1 (0.40) | FAAHFFAR4PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| EP-2305627-A1 | TETRACYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | Chisso Corporation (JP) | 2011-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | FAAH 725/4885FFAR4 546/4885MEN1 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.